# OnCo record nct05563220 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct05563220/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct05563220", "NCT05563220" ;
  schema:name "Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer"@en ;
  schema:alternateName "ELEVATE"@en ;
  schema:description "A phase 1/2 trial of Elacestrant, Alpelisib, Everolimus, Ribociclib, Palbociclib and Capivasertib in advanced solid tumours, run by Stemline Therapeutics, Inc., active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct05563220/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05563220> ;
  onco:status "active" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "1/2" ;
  schema:startDate "2023-01-24" ;
  onco:cancers <https://onco.cc/cancers/metastatic-cancer/> ;
  onco:technologies <https://onco.cc/technologies/endocrine-therapy/> ;
  onco:drugs <https://onco.cc/drugs/elacestrant/>, <https://onco.cc/drugs/alpelisib/>, <https://onco.cc/drugs/everolimus/>, <https://onco.cc/drugs/ribociclib/>, <https://onco.cc/drugs/palbociclib/>, <https://onco.cc/drugs/capivasertib/> ;
  onco:companies <https://onco.cc/companies/menarini/> .